Frontiers in nephrology最新文献

筛选
英文 中文
Frequency and factors associated with flare-ups in lupus patients with lupus nephritis in French Guiana. 法属圭亚那狼疮性肾炎患者发作的频率和相关因素。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-12 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1972371
Arriel Makembi Bunkete, Mamadou Mouctar Diallo, Jonathan Muamba Mutombo, Malika Belgrine, Gloria Ningaro Timem, Comlan Ney-Nicaise Vigan, Mohamed Sidibe, Timothé Davodoun, Irénée Djiconkpode, Tanguy Gbaguidi, Franklin Samou Fantcho
{"title":"Frequency and factors associated with flare-ups in lupus patients with lupus nephritis in French Guiana.","authors":"Arriel Makembi Bunkete, Mamadou Mouctar Diallo, Jonathan Muamba Mutombo, Malika Belgrine, Gloria Ningaro Timem, Comlan Ney-Nicaise Vigan, Mohamed Sidibe, Timothé Davodoun, Irénée Djiconkpode, Tanguy Gbaguidi, Franklin Samou Fantcho","doi":"10.3389/fneph.2026.1972371","DOIUrl":"10.3389/fneph.2026.1972371","url":null,"abstract":"<p><strong>Background: </strong>French Guiana ranks among the French overseas territories with the highest prevalence of systemic lupus erythematosus (SLE). However, local data on lupus flares and renal involvement remain limited. This study aimed to determine the frequency of lupus flares and identify associated factors among patients with lupus nephritis (LN) compared with those without renal involvement.</p><p><strong>Methods: </strong>We conducted an observational historical cohort study using data from the West Guyanese lupus cohort between January 2018 and December 2022. Patients with confirmed SLE were consecutively included and classified according to the presence or absence of LN. Clinical, biological, and immunological data were extracted from medical records. Lupus flare was defined as documented disease worsening requiring therapeutic intensification. Factors associated with flares were assessed using multivariable logistic regression.</p><p><strong>Results: </strong>Sixty-two patients were included, of whom 45 (72.6%) had LN. Overall, 53% experienced at least one flare. Flares occurred more frequently in patients with LN than in those without LN (62.2% vs. 29.4%). Higher anti-dsDNA and anti-Smith antibody levels, higher SLEDAI scores, fever, pleural effusion, and cutaneous manifestations were significantly associated with flares. In multivariable analysis, LN (OR 3.64; 95% CI 1.00-13.23; p=0.049) and higher anti-dsDNA antibody levels (p=0.033) were independently associated with flares.</p><p><strong>Conclusion: </strong>Lupus flares were frequent and occurred more often in patients with LN. LN and higher anti-dsDNA antibody levels were independently associated with flares, supporting close monitoring of patients with renal involvement to identify disease activity and optimize management.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1972371"},"PeriodicalIF":2.9,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiological discordance between clinical examination, bioimpedance spectroscopy, and lung ultrasound in maintenance hemodialysis patients without heart failure. 无心力衰竭维持性血液透析患者临床检查、生物阻抗谱和肺超声之间的生理差异。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-09 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.2000700
Irwing R Benites-Flores, Javier Rodríguez Revilla, Alvaro Taype-Rondan, Liliana C Fernández-Anticona, Pedro Augusto Prado Ramírez, Nelly Seminario Alegre, Celia Rodríguez Tudero, Esperanza Moral Berrio, Elena Jimenez Mayor, Avinash Chandu Nanwani, José C De la Flor
{"title":"Physiological discordance between clinical examination, bioimpedance spectroscopy, and lung ultrasound in maintenance hemodialysis patients without heart failure.","authors":"Irwing R Benites-Flores, Javier Rodríguez Revilla, Alvaro Taype-Rondan, Liliana C Fernández-Anticona, Pedro Augusto Prado Ramírez, Nelly Seminario Alegre, Celia Rodríguez Tudero, Esperanza Moral Berrio, Elena Jimenez Mayor, Avinash Chandu Nanwani, José C De la Flor","doi":"10.3389/fneph.2026.2000700","DOIUrl":"10.3389/fneph.2026.2000700","url":null,"abstract":"<p><strong>Background and objectives: </strong>Accurate volume assessment in maintenance hemodialysis remains challenging because no single bedside method fully characterizes extracellular fluid overload. We evaluated discordance among clinical examination, bioimpedance spectroscopy, and abbreviated six-zone lung ultrasound, the prevalence of subclinical pulmonary congestion, and factors associated with pulmonary congestion.</p><p><strong>Methods: </strong>In this single-center cross-sectional study, 116 adults receiving maintenance hemodialysis without clinically recognized heart failure underwent standardized clinical examination, whole-body bioimpedance spectroscopy, and predialysis six-zone lung ultrasound. Subclinical pulmonary congestion was defined as a prespecified total B-line count of ≥3 in clinically euvolemic patients. Agreement was assessed using Cohen's kappa, and independent associations were evaluated using multivariable Poisson regression.</p><p><strong>Results: </strong>Among 49 clinically euvolemic patients, 27 (55.1%) had subclinical pulmonary congestion, representing 23.3% of the cohort. Clinical examination showed fair agreement with lung ultrasound for ≥3 B-lines (κ = 0.28; 95% CI, 0.11-0.45), whereas agreement between lung ultrasound and bioimpedance-defined overhydration was slight (κ = 0.16; 95% CI, -0.03 to 0.35). Bioimpedance-derived overhydration, but not interdialytic weight gain, was independently associated with subclinical pulmonary congestion.</p><p><strong>Conclusion: </strong>Discordance among clinical examination, bioimpedance spectroscopy, and lung ultrasound was common and is consistent with the hypothesis that these modalities capture partially distinct aspects of volume status and pulmonary congestion. Abbreviated lung ultrasound frequently identified clinically occult pulmonary congestion despite apparent clinical euvolemia, supporting a multidimensional approach to bedside volume assessment in maintenance hemodialysis.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"2000700"},"PeriodicalIF":2.9,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease. 脂蛋白(a):降低慢性肾病患者心血管残留风险的潜在靶点。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-07 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1950030
Leonardo A Sechi, Luca Bulfone, Antonio Vacca, Jacopo Comand, Stefano Marcante, Gabriele Brosolo, Claudio Pagano, Cristiana Catena
{"title":"Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease.","authors":"Leonardo A Sechi, Luca Bulfone, Antonio Vacca, Jacopo Comand, Stefano Marcante, Gabriele Brosolo, Claudio Pagano, Cristiana Catena","doi":"10.3389/fneph.2026.1950030","DOIUrl":"10.3389/fneph.2026.1950030","url":null,"abstract":"<p><p>Epidemiological evidence demonstrates that atherosclerotic cardiovascular disease (ASCVD) is a major cause of death and disability in patients with chronic kidney disease (CKD). From the early stages of CKD, and in addition to specifically related conditions, the coexistence of traditional risk factors contributes to a process of accelerated atherosclerosis. In patients with CKD, increased cardiovascular risk persists even after correction of hypertension, dyslipidemia, and diabetes, indicating a residual risk likely related to additional subtle factors. Lipoprotein(a) [Lp(a)] is an LDL-like particle containing apoB100 covalently linked to apo(a) and is now recognized as a genetically determined risk factor for ASCVD. Following its initial description, Lp(a) aroused extraordinary interest, which then waned in the late-1990s due to the controversial results of some prospective studies and the lack of effective interventions to reduce its circulating levels. Over the past two decades, clinical studies have provided robust evidence supporting the causal and independent contribution of Lp(a) to ASCVD, also suggesting a significant contribution to residual cardiovascular risk. This contribution may be particularly significant in patients with CKD, who exhibit elevated Lp(a) levels from the earliest stages of disease. The recent development of potent Lp(a)-lowering drugs offers an exciting opportunity to effectively address residual risk in the general population and in patients with CKD. No data are yet available on their use in patients with CKD but pending future definition of their efficacy on cardiovascular outcomes, approval, dosing, and long-term safety, these drugs might possibly represent a useful tool for cardiovascular prevention in these patients.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1950030"},"PeriodicalIF":2.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13684331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping the aging kidney: a bibliometric atlas of cellular senescence and future frontiers since the 20th century. 绘制衰老肾脏:20世纪以来细胞衰老和未来前沿的文献计量图谱。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-07 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1905354
Jieyan Wang, Mengning Yang, Yifei Li, Yantong Wan, Xiaoying Zhan, Hui Liang
{"title":"Mapping the aging kidney: a bibliometric atlas of cellular senescence and future frontiers since the 20th century.","authors":"Jieyan Wang, Mengning Yang, Yifei Li, Yantong Wan, Xiaoying Zhan, Hui Liang","doi":"10.3389/fneph.2026.1905354","DOIUrl":"10.3389/fneph.2026.1905354","url":null,"abstract":"<p><strong>Background: </strong>Kidney disease is a major global public health challenge. The pathological mechanisms linking chronic kidney disease (CKD) and age-related kidney function decline are complex. Cellular senescence and its senescence-associated secretory phenotype (SASP) act as key links between kidney aging and disease progression. Although publications in this field have surged, a systematic bibliometric analysis is needed to outline its knowledge framework, research hotspots, and future trends. This study aims to quantitatively analyze global publication trends, core contributors (countries, institutions, journals, and authors), and cooperation networks to map the dynamic evolution of this field.</p><p><strong>Methods: </strong>We conducted a comprehensive literature search across both the Web of Science Core Collection (WoSCC) and Scopus databases to retrieve original articles and reviews concerning cellular senescence and kidney aging published between 2000 and 2025. After merging the datasets and removing duplicates, a meticulous bibliometric analysis was executed using Excel 365, CiteSpace, VOSviewer, and Bibliometrix (an R package) to map the knowledge framework and cooperation networks.</p><p><strong>Results: </strong>This analysis included 2,191 relevant papers involving 16,545 researchers. The overall publication volume showed significant growth, reaching a peak in 2025. The United States leads the field with the most publications and the highest citation frequency. China ranks second in publications but fourth in citations, reflecting a gap in research quality. The collaboration network indicates that the United States is the core node, maintaining close ties with countries like China and Germany. The <i>American Journal of Physiology-Renal Physiology</i> ranked first in publication volume, while the <i>Journal of the American Society of Nephrology</i> achieved the highest citation frequency. Xiang-Mei Chen and Anette Melk were identified as core contributing scholars. Keyword analysis established \"aging\" (825 times) and \"cellular senescence\" (330 times) as the central concepts. Emerging topics such as \"machine learning,\" \"ferroptosis,\" and \"Mendelian randomization\" are rapidly rising as research hotspots.</p><p><strong>Conclusion: </strong>This study maps the evolutionary trends of research on cellular senescence and related kidney diseases, identifying current frontiers and providing data to support future research. The rise of concepts like machine learning, ferroptosis, and Mendelian randomization marks a deep shift in the research paradigm, offering new perspectives for future scientific exploration.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1905354"},"PeriodicalIF":2.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of persistent C4d deposition on sequential protocol biopsies in ABO-incompatible kidney transplantation. abo血型不相容肾移植序贯活检中持续C4d沉积的临床意义。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-06 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1940137
Yu Kijima, Hideki Ishida, Takafumi Yagisawa, Toshihito Hirai, Kohei Unagami, Tomokazu Shimizu, Toshio Takagi
{"title":"Clinical significance of persistent C4d deposition on sequential protocol biopsies in ABO-incompatible kidney transplantation.","authors":"Yu Kijima, Hideki Ishida, Takafumi Yagisawa, Toshihito Hirai, Kohei Unagami, Tomokazu Shimizu, Toshio Takagi","doi":"10.3389/fneph.2026.1940137","DOIUrl":"https://doi.org/10.3389/fneph.2026.1940137","url":null,"abstract":"<p><strong>Introduction: </strong>C4d deposition is common after ABO-incompatible (ABOi) kidney transplantation and, unlike ABO-compatible grafts, is not necessarily indicative of antibody-mediated injury.</p><p><strong>Methods: </strong>Between 2015 and 2022, 254 ABOi kidney transplantations were performed at our center, and 69 recipients with paired 3-month and 1-year protocol biopsies were classified as persistently C4d-positive (n = 54) or C4d-negative/nonpersistent (n = 15). Pre-transplant background, cellular infiltration, chronic Banff lesions according to the Banff 2019 classification, graft function, and graft survival were compared.</p><p><strong>Results: </strong>Baseline anti-A/B titers, ABO combination, donor age, and donor relationship did not differ between the groups, whereas donor sex differed significantly (P = 0.014). Microvascular inflammation, defined as glomerulitis plus peritubular capillaritis ≥2, was observed in 6/54 recipients (11.1%) versus 1/15 (6.7%), and chronic changes, defined as interstitial fibrosis score ≥1, were observed in 27/54 (50.0%) versus 6/15 (40.0%); none of these differences reached statistical significance. Graft function and survival also did not differ significantly, although all four graft losses occurred in the persistent C4d-positive group. Three of these losses were attributable to chronic active antibody-mediated rejection, diagnosed at the 1-year biopsy in one recipient and later in two recipients.</p><p><strong>Discussion: </strong>Given the selected cohort and limited statistical power, these findings represent a failure to detect an association rather than evidence of equivalence. They are consistent with accommodation but require confirmation in larger, less-selected cohorts.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1940137"},"PeriodicalIF":2.9,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Light chain amyloidosis in a patient with low-grade B-cell lymphoma. 病例报告:轻链淀粉样变伴低级别b细胞淋巴瘤1例。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-06 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1959759
Alex Matthaeus, David Thomas, Hakan R Toka
{"title":"Case Report: Light chain amyloidosis in a patient with low-grade B-cell lymphoma.","authors":"Alex Matthaeus, David Thomas, Hakan R Toka","doi":"10.3389/fneph.2026.1959759","DOIUrl":"https://doi.org/10.3389/fneph.2026.1959759","url":null,"abstract":"<p><strong>Background: </strong>Light chain (AL) amyloidosis is typically associated with plasma cell dyscrasias but can rarely arise from low-grade B-cell non-Hodgkin lymphoma. Renal involvement may present with nephrotic-range proteinuria, acute kidney injury, edema, anasarca, and hypoalbuminemia. Recognizing lymphoma-associated AL amyloidosis is essential because diagnosis requires tissue confirmation, and treatment must target the underlying clonal B-cell disorder.</p><p><strong>Case: </strong>We report a rare case of severe renal AL amyloidosis in a patient with known low-grade B-cell non-Hodgkin lymphoma previously treated with rituximab. The patient presented with witnessed syncope, progressive peripheral edema, anasarca, and hypotension. Initial evaluation showed acute kidney injury with nephrotic-range proteinuria, including a urine protein-to-creatinine ratio greater than 10 g/g. Workup for autoimmune, infectious, and malignant causes of proteinuric kidney disease revealed positive hepatitis C antibody, mildly elevated serum lambda free light chains, a mildly decreased kappa-to-lambda ratio, and serum immunofixation positive for an IgM monoclonal lambda gammopathy. Renal biopsy demonstrated severe AL amyloidosis with predominant renal involvement. Bone marrow biopsy showed low-grade B-cell non-Hodgkin lymphoma involving 85% of the marrow, with CD20-positive immunophenotyping.</p><p><strong>Conclusion: </strong>This case highlights a rare presentation of renal AL amyloidosis secondary to low-grade B-cell non-Hodgkin lymphoma. Persistent nephrotic-range proteinuria in patients with B-cell lymphoma, particularly with IgM lambda monoclonal gammopathy, should prompt evaluation for amyloidosis with renal biopsy and hematologic assessment.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1959759"},"PeriodicalIF":2.9,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gd-IgA1-targeting therapy in IgA nephropathy ~what is pathogenic Gd-IgA1?~. Gd-IgA1靶向治疗IgA肾病~什么是致病的Gd-IgA1?
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-01 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1977707
Kazuaki Mori, Yoshihito Nihei, Yusuke Suzuki
{"title":"Gd-IgA1-targeting therapy in IgA nephropathy ~what is pathogenic Gd-IgA1?~.","authors":"Kazuaki Mori, Yoshihito Nihei, Yusuke Suzuki","doi":"10.3389/fneph.2026.1977707","DOIUrl":"10.3389/fneph.2026.1977707","url":null,"abstract":"<p><p>IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, and galactose-deficient IgA1 (Gd-IgA1) is widely recognized as the central pathogenic molecule in the current multi-hit model of IgAN. Over the past few decades, advances in our understanding of IgAN pathogenesis have driven the development of mechanism-based therapies targeting Gd-IgA1-producing cells and the pathways that regulate their differentiation and survival. Recent clinical trials have demonstrated marked reductions in circulating Gd-IgA1, accompanied by significant improvements in proteinuria and preservation of kidney function, highlighting the transition from non-specific disease-modifying therapies toward mechanism-based therapies in IgAN. However, optimizing the use of these emerging therapies requires a deeper understanding of the immune mechanisms responsible for pathogenic Gd-IgA1 production. In this review, we summarize current knowledge regarding the cellular sources and molecular pathways responsible for the production of Gd-IgA1, review recent advances in therapies targeting these cells, and discuss the emerging concept that specific Gd-IgA1 fractions, including IgA-type anti-mesangial cell autoantibodies (IgA-MESCA), may contribute to the disease pathogenesis.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1977707"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SGLT2 inhibitors as a strategy for volume management in peritoneal dialysis: a case series. SGLT2抑制剂作为腹膜透析容积管理策略:一个病例系列。
IF 2.9
Frontiers in nephrology Pub Date : 2026-09-29 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1942462
R Haridian Sosa Barrios, Miriam Domínguez-Tejedor, Raquel Moreno García, Víctor M Burguera Vion, Milagros Fernández Lucas, Maite E Rivera Gorrín
{"title":"SGLT2 inhibitors as a strategy for volume management in peritoneal dialysis: a case series.","authors":"R Haridian Sosa Barrios, Miriam Domínguez-Tejedor, Raquel Moreno García, Víctor M Burguera Vion, Milagros Fernández Lucas, Maite E Rivera Gorrín","doi":"10.3389/fneph.2026.1942462","DOIUrl":"https://doi.org/10.3389/fneph.2026.1942462","url":null,"abstract":"<p><p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in chronic kidney disease, yet their role in peritoneal dialysis (PD) remains largely unexplored, and clinical experience is limited. We describe, at the individual-patient level, seven consecutive patients treated with an SGLT2i at a single centre (median age 69 years, range 43-73; five men; one with type 2 diabetes; six dapagliflozin, one empagliflozin). The PD prescription was not modified during treatment, and ultrafiltration refers to the 24-hour drained volume. In the four patients in whom the drug was added to established, unchanged PD, ultrafiltration rose in three and fell in one; the single non-responder was also the only low-average transporter and was later transferred to haemodiafiltration. Both patients anuric at baseline increased their ultrafiltration, and in one of them PD was the only feasible modality. Peritoneal transport category was unchanged wherever paired equilibration tests were available. Serum urate fell in the patients with preserved diuresis but not in those who were anuric, whereas the largest ultrafiltration gain occurred in a patient anuric throughout, dissociating the peritoneal response from any renal effect. The erythropoietin resistance index fell in all treated patients, although the magnitude was clinically relevant in a minority and must be read alongside the haemoglobin trajectory. No patient developed anuria <i>de novo</i>. One patient died of fungal peritonitis in the context of documented non-adherence, an event reported here with its mechanistic implications. These observations support a direct peritoneal mode of action and warrant prospective evaluation with surveillance for fungal infection.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1942462"},"PeriodicalIF":2.9,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-GBM disease shortly after clinically presumed ANCA-associated vasculitis in an 85-year-old patient: a case report and literature review. 85岁患者临床推定为anca相关血管炎后不久出现抗gbm疾病:病例报告及文献回顾
IF 2.9
Frontiers in nephrology Pub Date : 2026-09-28 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1967122
Hiroki Ito, Hiyu Abe, Yuya Suzuki, Kentaro Yano, Fumiya Sato, Takaki Numahata, Risa Ishikawa, Akari Endo-Matsumoto, Keiji Matsumoto, Tsubasa Yuki, Ayaka Kamada, Hideaki Hashimoto, Go Anan, Katsuya Ishiyama, Takuo Hirose, Takefumi Mori
{"title":"Anti-GBM disease shortly after clinically presumed ANCA-associated vasculitis in an 85-year-old patient: a case report and literature review.","authors":"Hiroki Ito, Hiyu Abe, Yuya Suzuki, Kentaro Yano, Fumiya Sato, Takaki Numahata, Risa Ishikawa, Akari Endo-Matsumoto, Keiji Matsumoto, Tsubasa Yuki, Ayaka Kamada, Hideaki Hashimoto, Go Anan, Katsuya Ishiyama, Takuo Hirose, Takefumi Mori","doi":"10.3389/fneph.2026.1967122","DOIUrl":"10.3389/fneph.2026.1967122","url":null,"abstract":"<p><strong>Introduction: </strong>Sequential emergence of anti-glomerular basement membrane (GBM) disease after anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is rare.</p><p><strong>Case presentation: </strong>An 85-year-old woman presented with fever, edema, elevated myeloperoxidase (MPO)-ANCA, mild urinary abnormalities, markedly elevated urinary tubular injury markers, and negative serum anti-GBM antibodies measured by chemiluminescent enzyme immunoassay. Renal biopsy was not performed because of advanced age, severe dementia, antiplatelet therapy, and the family's preference for non-invasive management. She was clinically presumed to have AAV and achieved apparent clinical remission with prednisolone alone, although MPO-ANCA remained positive. However, 2.5 months after the initial AAV diagnosis, she developed rapidly progressive kidney failure requiring dialysis, accompanied by severe hematuria, increased proteinuria, urinary casts, and markedly elevated anti-GBM antibodies. Clinically diagnosed anti-GBM disease was treated with methylprednisolone pulse therapy, prednisolone, plasma exchange, and hemodialysis. Although renal recovery was not achieved, anti-GBM antibodies became negative, and she remained clinically stable on maintenance hemodialysis for over 4 years while receiving low-dose prednisolone.</p><p><strong>Conclusion: </strong>This case suggests that anti-GBM disease can emerge shortly after apparent clinical remission of AAV. ANCA-mediated GBM injury and age-related GBM changes may contribute to subsequent anti-GBM autoimmunity, although these mechanisms remain hypothetical in this patient. Prompt anti-GBM antibody testing should be considered when a rapid, unexplained decline in kidney function occurs during or after AAV treatment.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1967122"},"PeriodicalIF":2.9,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of renal and patient survival in lupus nephritis: a 28-year single-center cohort study. 红斑狼疮肾炎患者肾脏和生存的预测因素:一项28年单中心队列研究。
IF 2.9
Frontiers in nephrology Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1945616
Alexandra Vrabie, Bogdan Obrişcă, Bogdan Sorohan, Roxana Jurubiţă, Camelia Achim, Diana Silvia Zilişteanu, Andreea Gabriela Andronesi, Gabriela Lupuşoru, Elena Emanuela Rusu, Raluca Bobeică, Elena Georgia Micu, Sonia Bălănică, Andreea Berechet, Valentin Mocanu, Ştefan Lujinschi, Nicu Caceaune, Gener Ismail
{"title":"Predictors of renal and patient survival in lupus nephritis: a 28-year single-center cohort study.","authors":"Alexandra Vrabie, Bogdan Obrişcă, Bogdan Sorohan, Roxana Jurubiţă, Camelia Achim, Diana Silvia Zilişteanu, Andreea Gabriela Andronesi, Gabriela Lupuşoru, Elena Emanuela Rusu, Raluca Bobeică, Elena Georgia Micu, Sonia Bălănică, Andreea Berechet, Valentin Mocanu, Ştefan Lujinschi, Nicu Caceaune, Gener Ismail","doi":"10.3389/fneph.2026.1945616","DOIUrl":"https://doi.org/10.3389/fneph.2026.1945616","url":null,"abstract":"<p><strong>Introduction: </strong>Despite advances in the understanding and treatment of lupus nephritis (LN), long-term renal and patient outcomes remain suboptimal. Identifying reliable predictors of prognosis and early treatment response is essential for improving risk stratification and guiding management.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of patients with biopsy-proven LN. Long-term renal and patient survival, renal response at 6 and 12 months, and predictors of a composite outcome (doubling of serum creatinine, end-stage kidney disease [ESKD], or death) were evaluated.</p><p><strong>Results: </strong>A total of 147 patients were included, with a median follow-up of 39.5 months. 10.3% of patients had a doubling of serum creatinine, 11.0% progressed to ESKD, and 6.8% died. Proteinuria <0.7 g/day was achieved by 49.1% and 54.4% of patients at 6 and 12 months, respectively. In multivariate analysis, baseline predictors of the composite outcome included age >50 years, proteinuria ≥3 g/day, and hemoglobin <10 g/dL, while an activity index ≥9 and low baseline C4 levels showed a protective trend. Achieving proteinuria <0.7 g/day at 12 months emerged as the strongest protective factor. A prognostic score demonstrated good discrimination (area under the curve [AUC] 0.82), which improved further with the addition of proteinuria at 12 months (AUC 0.86).</p><p><strong>Conclusions: </strong>In this biopsy-proven LN cohort, early renal response, particularly proteinuria <0.7 g/day at 12 months, was the strongest predictor of long-term renal and patient survival. These findings support a dynamic, response-based approach to prognostication in LN and provide the basis for a clinically applicable prognostic score that requires external validation.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1945616"},"PeriodicalIF":2.9,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书